At the news
? BULLISHIMPACT 6/10 8-K filed Aug 31, 2026 at 08:08 ET
Karyopharm announced submission of an sNDA to the FDA seeking Accelerated Approval for XPOVIO (selinexor) in combination with ruxolitinib for myelofibrosis, based on Phase 3 SENTRY trial data showing a promising overall survival signal. Priority Review was requested, which could yield a six-month review cycle. FDA acceptance and review timeline decisions are expected in Q4 2026.
- sNDA submitted for XPOVIO (selinexor) + ruxolitinib in myelofibrosis under Accelerated Approval pathway
- Priority Review requested; if granted, review period would be approximately six months
- FDA decision on sNDA filing acceptance and review timelines expected in Q4 2026
- Submission based on Phase 3 SENTRY trial data with a positive benefit-risk profile and overall survival signal
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access